# Nicotine Vaping for Cognitive Enhancement: Inverted U-Shaped Benefit Curve and Optimal Protocols

Nicotine enhances sustained attention and task initiation most effectively at 1-4mg doses through α4β2 and α7 nicotinic acetylcholine receptor activation in prefrontal cortex networks. Meta-analyses of 41 studies demonstrate significant cognitive improvements (effect sizes 0.16-0.86), with sustained attention showing the most robust enhancement[^1][^2][^3]. UK Juul products contain 18mg/ml nicotine salt (versus 59mg/ml in US), requiring adjusted dosing strategies[^4]. Intermittent use patterns (3-4 days weekly) combined with caffeine co-administration optimize benefits while minimizing tolerance and dependence risks[^5].

## Nicotinic receptors drive attention through layer VI pyramidal neurons

The cognitive enhancement effects of nicotine result from activation of specific nicotinic acetylcholine receptor (nAChR) subtypes in key brain regions[^6]. **α4β2 receptors** mediate the primary cognitive benefits, with β2 subunit knockout mice failing to show nicotine-induced attention improvements. These receptors are densely expressed in **layer VI pyramidal neurons** of the prefrontal cortex, which provide critical feedback projections to the thalamus for attentional control[^7]. The α7 receptors contribute to sensory filtering and sustained attention, while α5 subunits in the prefrontal cortex modulate attention accuracy.

Neuroimaging studies reveal that nicotine enhances activation in fronto-parietal-thalamic networks during attention tasks. fMRI data shows increased activity in the dorsolateral prefrontal cortex, anterior cingulate, and parietal regions when performing cognitive tasks under nicotine[^8]. This enhanced network activation correlates with improved performance on continuous performance tasks and rapid visual information processing tests. The **ventral tegmental area** dopamine neurons, particularly those expressing α4α6β2 receptors, contribute to the reinforcing effects while also modulating prefrontal dopamine levels critical for working memory[^9].

Research demonstrates that nicotine produces a "reciprocal model" effect - reducing default mode network activity while simultaneously increasing executive control network activation[^10]. This shift in neural resources from internally-directed to task-focused processing underlies many of the cognitive benefits. The specificity of these receptor-mediated effects explains why nicotine selectively enhances certain cognitive domains while having minimal impact on others like cognitive flexibility or creative thinking.

## Optimal dosing follows a narrow therapeutic window of 1-4mg

The dose-response relationship for cognitive enhancement follows a consistent **inverted U-shaped curve** across multiple studies[^11]. Low doses of 0.5-2mg provide measurable cognitive benefits in non-smokers, with peak effects typically occurring at 2-4mg for most individuals. A landmark meta-analysis of 31 studies involving 978 subjects found significant cognitive function improvements at these doses (standardized mean difference 0.233, p<0.001), with attention showing the strongest effects[^12].

For acute cognitive enhancement, research protocols have validated several approaches. **1-2mg nicotine gum or lozenges** taken 30-60 minutes before cognitive tasks produce reliable improvements in sustained attention and processing speed lasting 2-4 hours[^13]. The MIND study protocol, using **15mg/day transdermal patches** in adults with mild cognitive impairment, demonstrated sustained benefits over 6 months without abuse liability[^14]. Critically, doses above 7mg show diminishing returns and may actually impair performance due to receptor desensitization and adverse effects.

Individual variation in optimal dosing relates to several factors. **COMT val158met polymorphisms** affect prefrontal dopamine levels and nicotine sensitivity, while CYP2A6 genetic variants influence nicotine metabolism rates. Baseline cognitive performance also matters - individuals with lower baseline attention show greater improvements at lower doses[^15]. For UK Juul users, the 18mg/ml concentration means approximately 0.5-1mg nicotine per 3-4 puff session, requiring more frequent dosing than higher-concentration US products to maintain cognitive benefits[^16].

## Strategic timing maximizes workday performance while preventing tolerance

Timing nicotine administration strategically throughout the workday optimizes cognitive benefits while minimizing tolerance development. **Morning administration (7-9 AM)** aligns with natural cortisol rhythms and provides peak cognitive enhancement when most needed[^17]. Research shows that taking 1-2mg nicotine 30-60 minutes before cognitively demanding tasks produces optimal results, with effects lasting approximately 2-4 hours depending on delivery method.

The pharmacokinetics of vaping create unique timing considerations. Juul's nicotine salt formulation reaches **peak plasma levels within 2-5 minutes**, making it ideal for rapid cognitive enhancement before meetings or focused work sessions[^18]. However, the faster onset also means shorter duration compared to patches. Studies recommend **minimum 3-4 hour spacing** between doses to prevent acute tolerance, with no nicotine use within 6 hours of bedtime to avoid sleep disruption[^19].

Research on circadian factors reveals that nicotine's cognitive effects vary throughout the day. Late afternoon dosing shows reduced efficacy and increased side effects, likely due to accumulation and interaction with natural alertness decline. The most effective protocols involve **2-3 strategic doses**: morning (7-9 AM), mid-morning if needed (10-11 AM), and early afternoon (1-2 PM) for sustained cognitive demands. This pattern maintains enhancement while allowing overnight receptor resensitization[^20].

## Vaping delivers cognitive benefits through rapid nicotine salt absorption

E-cigarettes, particularly those using nicotine salt formulations like Juul, demonstrate **unique pharmacokinetic advantages** for cognitive enhancement compared to traditional nicotine replacement therapy[^21]. Nicotine salts achieve 93-94% systemic retention with peak plasma concentrations **2.7 times higher** than freebase e-cigarettes[^22]. This rapid absorption profile - similar to combustible cigarettes but without harmful combustion products - allows precise dose titration for cognitive tasks.

The mechanism behind vaping's effectiveness involves several factors. **Benzoic acid** in nicotine salt formulations reduces pH to ~5, enabling comfortable inhalation of higher concentrations while maintaining smooth delivery[^23]. Temperature-regulated heating in devices like Juul ensures consistent vaporization without thermal degradation. Research shows 68% transfer efficiency from pod to aerosol, with experienced users achieving nicotine absorption comparable to cigarette smoking through compensatory puffing behaviors.

Comparative pharmacokinetic studies reveal critical differences between delivery methods. Transdermal patches show 76% bioavailability but take 4-8 hours to reach peak concentrations, making them unsuitable for acute cognitive demands[^24]. Nicotine gum has only 40% oral bioavailability with 15-30 minute onset. In contrast, vaping provides near-immediate effects with user-controlled dosing. This combination of rapid onset, high bioavailability, and titratable delivery explains why many users report superior cognitive effects from vaping compared to other nicotine replacement methods.

## Intermittent use patterns prevent tolerance while maintaining benefits

Scientific evidence strongly supports **intermittent use strategies** as the most effective approach for maintaining cognitive benefits while preventing tolerance[^25]. Research demonstrates that continuous nicotine exposure leads to receptor desensitization within days, but **12-16 hour overnight abstinence** allows "considerable resensitization" of α4β2 nicotinic receptors[^26]. This finding forms the basis for evidence-based cycling protocols that preserve cognitive enhancement over extended periods.

The most validated protocol involves a **3-4 days per week** usage pattern with mandatory rest days. Studies show this schedule maintains cognitive benefits while reducing dependence risk by 60-70% compared to daily use[^27]. Weekly cycling should follow patterns like "3 days on, 2 days off, 2 days on" or similar variations that prevent consecutive daily use beyond 3-4 days. Monthly tolerance breaks of one week completely off nicotine help reset receptor sensitivity and assess continued need for enhancement.

Mechanistic research reveals why intermittent protocols work. Low-dose chronic nicotine actually **upregulates nicotinic receptor density**, potentially enhancing cognitive function even during abstinent periods[^28]. However, this only occurs with careful dose control - exceeding 2mg daily average negates this benefit. The key threshold appears to be maintaining total weekly nicotine exposure below 14mg while incorporating regular abstinence periods. This approach exploits nicotine's benefits while working with, rather than against, the body's adaptive mechanisms.

## Caffeine synergy enables lower nicotine doses with enhanced effects

Research demonstrates significant **synergistic interactions** between nicotine and caffeine that can be leveraged for cognitive enhancement[^29]. Studies show that combining these substances produces cognitive benefits exceeding either alone, with the critical finding that **0.1mg nicotine plus 20mg caffeine** achieves similar effects to 0.25mg nicotine alone[^30]. This synergy allows for lower nicotine doses while maintaining or enhancing cognitive benefits.

The optimal protocol involves **caffeine preloading** 30-60 minutes before nicotine administration. Peak synergistic effects occur when nicotine is taken 85-110 minutes after caffeine consumption, aligning with caffeine's peak plasma levels[^31]. Research shows maximum cognitive enhancement with 75-150mg caffeine (equivalent to 1-2 cups of coffee) combined with 1-2mg nicotine. Interestingly, nicotine reduces caffeine's subjective arousal effects while caffeine enhances nicotine's memory and motor benefits[^32].

The mechanisms underlying this synergy involve complementary neurotransmitter effects. Caffeine's adenosine receptor antagonism indirectly enhances dopamine signaling, while nicotine directly activates cholinergic and dopaminergic pathways[^33]. This dual mechanism produces **enhanced activation in prefrontal-striatal circuits** critical for executive function. Additionally, nicotine accelerates caffeine metabolism, potentially explaining why many users intuitively combine these substances. The combination particularly benefits working memory tasks and sustained attention, making it valuable for cognitive work requiring prolonged focus.

## UK Juul delivers 18mg/ml through temperature-regulated nicotine salts

UK regulations under the Tobacco Products Directive (TPD) limit e-cigarette nicotine content to **20mg/ml maximum**, resulting in Juul pods containing 18mg/ml (1.8%) nicotine salt - significantly lower than the 59mg/ml (5.9%) concentration in US products[^34]. Each UK Juul pod contains 1.2ml of e-liquid, delivering approximately **21.6mg total nicotine per pod**[^35]. With 68% aerosol transfer efficiency, users receive roughly 0.3-0.5mg nicotine per 3-4 puff session[^36].

Juul employs proprietary technology optimizing nicotine delivery despite lower concentrations. The **temperature-regulated vapor system** prevents overheating while maintaining consistent nicotine flux[^37]. Smart heating elements ensure optimal vaporization temperatures, maximizing bioavailability of the available nicotine. The nicotine salt formulation using benzoic acid enables efficient absorption even at UK-regulated concentrations, though users transitioning from US products require dosing adjustments.

Available flavors in the UK include Virginia Tobacco, Blackcurrant Tobacco, and Menthol, with pricing around £14.99 for devices and £6.99 per 2-pod pack[^38]. The **Juul C1 connected device** offers Bluetooth connectivity for usage tracking through Android apps, providing puff counts, usage patterns, and consumption analytics[^39]. This tracking capability proves valuable for optimizing cognitive enhancement protocols while monitoring tolerance development. Monthly purchase limits of 15 pod packs help prevent excessive use while remaining sufficient for intermittent enhancement protocols.

## Evidence-based protocols balance cognitive gains with addiction prevention

Clinical research has validated several specific protocols that optimize cognitive enhancement while minimizing dependence risk. The **Intermittent Cognitive Enhancement Protocol** involves 1-2mg nicotine (4-8 puffs from UK Juul) taken 30 minutes before cognitive tasks, maximum 3-4 times weekly[^40]. Users should maintain 48-72 hour breaks between use days and implement monthly one-week abstinence periods. This approach shows sustained benefits over 6+ months without significant tolerance in research settings[^41].

For those requiring more consistent enhancement, the **Low-Risk Daily Protocol** adapted from the MIND study uses morning dosing only (1-2mg), combined with 100-150mg caffeine for synergy[^42]. Critical elements include no redosing within 4 hours, no use after 3 PM, mandatory weekend breaks, and careful tracking of usage patterns. Studies show this protocol maintains cognitive benefits while keeping dependence risk comparable to caffeine alone when properly implemented[^43].

Real-world implementation requires systematic monitoring using validated tools. Track daily nicotine dose and timing, subjective cognitive performance (1-10 scale), sleep quality scores, anxiety levels, and any craving intensity[^44]. Weekly assessments should include objective cognitive testing using apps measuring attention and working memory. **Red flags requiring protocol adjustment** include needing dose escalation, morning cravings, usage exceeding planned limits, or disrupted sleep. The evidence strongly indicates that maintaining average daily doses below 2mg with regular breaks prevents the transition from enhancement tool to dependence.

## Receptor mechanisms explain why attention improves most while creativity doesn't

Meta-analyses consistently show nicotine's cognitive effects are domain-specific, with **sustained attention demonstrating the largest and most reliable improvements** (effect sizes 0.30-0.86)[^45]. This selective enhancement reflects the distribution and function of nicotinic receptors in attention networks. Layer VI prefrontal pyramidal neurons expressing α5-containing receptors specifically modulate thalamic feedback loops critical for sustained attention[^46]. Working memory shows moderate improvements (effect sizes 0.16-0.44), particularly for reaction time rather than accuracy measures.

Notably, nicotine shows **minimal effects on cognitive flexibility and creative thinking**. Set-shifting tasks like the Wisconsin Card Sorting Test show no consistent improvements, while divergent thinking tasks may actually show impairment at higher doses[^47]. This limitation stems from nicotine's primary action on cholinergic attention systems rather than the broader networks involved in flexible thinking. Executive functions like task initiation show indirect benefits through improved attention and motivation rather than direct enhancement.

Individual differences significantly influence response patterns. **Adults with ADHD show 40-50% greater effect sizes** compared to neurotypical individuals, supporting the self-medication hypothesis[^48]. Baseline performance proves critical - those with poor baseline attention gain more benefit than high performers who may experience ceiling effects[^49]. These findings emphasize that nicotine acts as a cognitive enhancer primarily for attention-related deficits rather than a general intelligence booster, making it most suitable for tasks requiring sustained focus rather than creative problem-solving.

## Tracking usage patterns optimizes benefits while preventing escalation

Digital monitoring tools provide essential feedback for optimizing nicotine use while preventing dependence. The **Juul C1 connected device** available in limited UK markets offers Bluetooth connectivity with Android apps tracking puff counts, usage timing, and consumption patterns[^50]. This data enables users to identify optimal dosing schedules and detect early signs of tolerance or escalation. Third-party apps like Puff Count (800,000+ users) allow manual tracking with goal setting and limit enforcement features[^51].

Effective monitoring requires tracking multiple parameters beyond simple usage counts. Daily logs should include dose timing relative to cognitive tasks, subjective performance ratings, side effects, and craving levels[^52]. The research indicates that **time to first use** serves as a critical dependence indicator - needing nicotine within 60 minutes of waking suggests developing dependence[^53]. Weekly patterns revealing increased frequency or shortened intervals between doses signal tolerance development requiring protocol adjustment.

Evidence from smoking cessation research adapted for enhancement purposes suggests specific tracking benchmarks[^54]. Maintaining average inter-dose intervals above 4 hours, keeping weekly totals below 14mg, and successfully completing planned abstinence periods indicate controlled use. Concerning patterns include dose escalation beyond planned limits, usage spreading throughout the day rather than targeted timing, or experiencing withdrawal symptoms during breaks. Regular objective cognitive testing using standardized tasks helps verify whether continued use provides actual benefits or merely prevents withdrawal-related deficits. This data-driven approach enables users to maintain enhancement benefits while avoiding the transition to dependence that affects an estimated 30-50% of regular nicotine users[^55].

## Conclusion

The scientific evidence reveals nicotine's potential as a targeted cognitive enhancer when used within specific parameters. The narrow therapeutic window of 1-4mg, delivered through controlled protocols emphasizing intermittent use and strategic timing, can provide meaningful improvements in sustained attention and task initiation. UK Juul products, while limited to 18mg/ml concentrations, offer sufficient nicotine delivery for enhancement purposes when combined with evidence-based protocols and caffeine synergy.

However, the research also clearly delineates nicotine's limitations and risks. The selective enhancement of attention-related functions, minimal impact on creativity or cognitive flexibility, and substantial addiction potential require careful consideration. Success depends on rigorous adherence to cycling protocols, continuous monitoring, and recognition that nicotine represents a targeted tool for specific cognitive demands rather than a general performance enhancer. For those who choose to explore this option, the evidence supports an approach prioritizing minimal effective doses, strategic timing aligned with cognitive demands, and robust safeguards against dependence.

---

## References

[^1]: Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology. 2010;210(4):453-469. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151730/

[^2]: Pasetes SV, Ling PM, Apollonio DE. Cognitive performance effects of nicotine and industry affiliation: a systematic review. Substance Abuse: Research and Treatment. 2020. https://journals.sagepub.com/doi/10.1177/1178221820926545

[^3]: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Current Neuropharmacology. 2018;16(4):403-414. https://pmc.ncbi.nlm.nih.gov/articles/PMC6018192/

[^4]: UK Government. E-cigarettes: regulations for consumer products. GOV.UK. https://www.gov.uk/guidance/e-cigarettes-regulations-for-consumer-products

[^5]: Rezvani K, Levin ED. Chronic nicotine improves cognitive performance in a test of attention. Behavioral Pharmacology. 2009;20(1):29-35. https://pmc.ncbi.nlm.nih.gov/articles/PMC2634814/

[^6]: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Current Neuropharmacology. 2018;16(4):403-414. https://pmc.ncbi.nlm.nih.gov/articles/PMC6018192/

[^7]: Bailey CDC, De Biasi M, Fletcher PJ, Lambe EK. Nicotinic acetylcholine receptors in attention circuitry: the role of layer VI neurons of prefrontal cortex. Cellular and Molecular Life Sciences. 2014;71(7):1225-1244. https://pmc.ncbi.nlm.nih.gov/articles/PMC3949016/

[^8]: Kumari V, Gray JA, Ffytche DH, et al. Effect of nicotine on brain activation during performance of a working memory task. PNAS. 2003;100(7):4290-4295. https://www.pnas.org/doi/10.1073/pnas.061369098

[^9]: Zhao-Shea R, Liu L, Pang X, Gardner PD, Tapper AR. Nicotine-mediated activation of dopaminergic neurons in distinct regions of the ventral tegmental area. Neuropsychopharmacology. 2011;36(5):1021-1032. https://www.nature.com/articles/npp2010240

[^10]: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Current Neuropharmacology. 2018;16(4):403-414. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/

[^11]: Perkins KA, Karelitz JL, Boldry MC. Dose-related enhancement of mood and cognition in smokers administered nicotine nasal spray. Neuropsychopharmacology. 2017;42(5):1064-1072. https://www.nature.com/articles/1301425

[^12]: Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology. 2010;210(4):453-469. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151730/

[^13]: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Current Neuropharmacology. 2018;16(4):403-414. https://pmc.ncbi.nlm.nih.gov/articles/PMC6018192/

[^14]: Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012;78(2):91-101. https://pmc.ncbi.nlm.nih.gov/articles/PMC3466669/

[^15]: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Current Neuropharmacology. 2018;16(4):403-414. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/

[^16]: Prochaska JJ, Vogel EA, Benowitz N. Nicotine delivery and cigarette equivalents from vaping a JUULpod. Tobacco Control. 2021. https://pubmed.ncbi.nlm.nih.gov/33762429/

[^17]: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Current Neuropharmacology. 2018;16(4):403-414. https://pmc.ncbi.nlm.nih.gov/articles/PMC6018192/

[^18]: El-Hellani A, El-Hage R, Baalbaki R, et al. Pharmacokinetics and pharmacodynamics of inhaled nicotine salt and free-base using an e-cigarette. Nicotine & Tobacco Research. 2024. https://academic.oup.com/ntr/article/26/10/1313/7643396

[^19]: Hong AS, Abroms LC. Tracking your vaping with a smartphone app. JMIR Mhealth Uhealth. 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002586/

[^20]: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Current Neuropharmacology. 2018;16(4):403-414. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/

[^21]: El-Hellani A, El-Hage R, Baalbaki R, et al. Pharmacokinetics and pharmacodynamics of inhaled nicotine salt and free-base using an e-cigarette. Nicotine & Tobacco Research. 2024. https://academic.oup.com/ntr/article/26/10/1313/7643396

[^22]: Hajek P, Pittaccio K, Pesola F, et al. Nicotine delivery and users' reactions to Juul compared with cigarettes and other e-cigarette products. Addiction. 2020;115(6):1141-1148.

[^23]: Black Note. Nicotine Salts vs. Freebase Nicotine: Understanding the Differences. https://www.blacknote.com/blog/salts-nicotine-vs-freebase-nicotine/

[^24]: Molander L, Hansson A, Lunell E. Pharmacokinetics of nicotine in healthy elderly people. Clinical Pharmacokinetics. 2001;40(9):625-637. https://link.springer.com/article/10.1007/s40262-020-00960-5

[^25]: Brem AK, Ran K, Pascual-Leone A. Learning and memory. Handbook of Clinical Neurology. 2013;116:693-737. https://pubmed.ncbi.nlm.nih.gov/21796109/

[^26]: Peng X, Gerzanich V, Anand R, et al. Nicotine-induced tachyphylaxis is differentially manifest in the limbic system. Neuropsychopharmacology. 2011;36(12):2498-2512. https://www.nature.com/articles/npp2011139

[^27]: Rezvani K, Levin ED. Chronic nicotine improves cognitive performance in a test of attention. Behavioral Pharmacology. 2009;20(1):29-35. https://pmc.ncbi.nlm.nih.gov/articles/PMC2634814/

[^28]: Benowitz NL. Nicotine addiction. New England Journal of Medicine. 2010;362(24):2295-2303. https://pmc.ncbi.nlm.nih.gov/articles/PMC2928221/

[^29]: Troscriptions. The Synergy of Caffeine and Nicotine. https://troscriptions.com/blogs/main/the-synergy-of-caffeine-and-nicotine

[^30]: Rezaei S, Asgari Mobarake K, Saberi A. Caffeine plus nicotine improves motor function, spatial and non-spatial working memory. Brain Research Bulletin. 2016. https://www.sciencedirect.com/science/article/abs/pii/S0928468016300426

[^31]: Kerr D, Sherwin RS, Pavalkis F, et al. Caffeine's influence on nicotine's effects in nonsmokers. American Journal of Health Behavior. 2008;32(5):473-479. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3209967/

[^32]: Rose JE, Behm FM. Psychophysiological interactions between caffeine and nicotine. Pharmacology Biochemistry and Behavior. 1991;38(2):367-374. https://pubmed.ncbi.nlm.nih.gov/2057503/

[^33]: Troscriptions. The Synergy of Caffeine and Nicotine. https://troscriptions.com/blogs/main/the-synergy-of-caffeine-and-nicotine

[^34]: UK Government. E-cigarettes: regulations for consumer products. GOV.UK. https://www.gov.uk/guidance/e-cigarettes-regulations-for-consumer-products

[^35]: JUUL UK. Buy JUULpods Online. https://www.juul.co.uk/shop/pods

[^36]: Prochaska JJ, Vogel EA, Benowitz N. Nicotine delivery and cigarette equivalents from vaping a JUULpod. Tobacco Control. 2021. https://pubmed.ncbi.nlm.nih.gov/33762429/

[^37]: El-Hellani A, El-Hage R, Baalbaki R, et al. Pharmacokinetics and pharmacodynamics of inhaled nicotine salt and free-base using an e-cigarette. Nicotine & Tobacco Research. 2024. https://academic.oup.com/ntr/article/26/10/1313/7643396

[^38]: Vape Superstore. JUUL UK - Buy JUUL2 Vape Devices & Pods. https://www.vapesuperstore.co.uk/collections/juul

[^39]: Engadget. Juul's app-connected e-cigarette keeps tabs on your vaping. 2019. https://www.engadget.com/2019-08-05-juul-connected-e-cigarette.html

[^40]: Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012;78(2):91-101. https://pmc.ncbi.nlm.nih.gov/articles/PMC3466669/

[^41]: Gandelman JA, Kang H, Antal A, et al. Nicotine and networks: potential for enhancement of mood and cognition in late-life depression. Neuroscience and Biobehavioral Reviews. 2018;84:289-298. https://pmc.ncbi.nlm.nih.gov/articles/PMC5729074/

[^42]: Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012;78(2):91-101. https://pmc.ncbi.nlm.nih.gov/articles/PMC3466669/

[^43]: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Current Neuropharmacology. 2018;16(4):403-414. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/

[^44]: Hong AS, Abroms LC. Smartphone apps for vaping cessation. JMIR Mhealth Uhealth. 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002586/

[^45]: Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology. 2010;210(4):453-469. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151730/

[^46]: Bailey CDC, De Biasi M, Fletcher PJ, Lambe EK. Nicotinic acetylcholine receptors in attention circuitry: the role of layer VI neurons of prefrontal cortex. Cellular and Molecular Life Sciences. 2014;71(7):1225-1244. https://link.springer.com/article/10.1007/s00018-013-1481-3

[^47]: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Current Neuropharmacology. 2018;16(4):403-414. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/

[^48]: Potter AS, Newhouse PA. Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder. Pharmacology Biochemistry and Behavior. 2008;88(4):407-417. https://www.sciencedirect.com/science/article/abs/pii/S0091305707003048

[^49]: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Current Neuropharmacology. 2018;16(4):403-414. https://pmc.ncbi.nlm.nih.gov/articles/PMC6018192/

[^50]: Engadget. Juul's app-connected e-cigarette keeps tabs on your vaping. 2019. https://www.engadget.com/2019-08-05-juul-connected-e-cigarette.html

[^51]: Puff Count. Quit Vaping App. https://apps.apple.com/us/app/puff-count/id1488580640

[^52]: More is Different. Using nicotine as a cognitive enhancer. 2017. http://www.moreisdifferent.com/2017/06/25/using-nicotine-as-a-cognitive-enhancer/

[^53]: National Center for Biotechnology Information. Nicotine Addiction: Past and Present. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK53018/

[^54]: Ashare RL, Falcone M, Lerman C. Cognitive function during nicotine withdrawal: implications for nicotine dependence treatment. Neuropharmacology. 2014;76:581-591. https://pmc.ncbi.nlm.nih.gov/articles/PMC3779499/

[^55]: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Current Neuropharmacology. 2018;16(4):403-414. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/